Corvel Corp CRVL
We take great care to ensure that the data presented and summarized in this overview for CORVEL CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CRVL
View all-
Kayne Anderson Rudnick Investment Management LLC Los Angeles, CA5.71MShares$570 Million1.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.23MShares$323 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.83MShares$183 Million0.33% of portfolio
-
Black Rock Inc. New York, NY1.47MShares$147 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.44MShares$144 Million0.04% of portfolio
-
State Street Corp Boston, MA1.07MShares$107 Million0.01% of portfolio
-
Neuberger Berman Group LLC New York, NY839KShares$83.8 Million0.08% of portfolio
-
Geode Capital Management, LLC Boston, MA803KShares$80.2 Million0.01% of portfolio
-
Boston Trust Walden Corp678KShares$67.7 Million0.56% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD592KShares$59.1 Million0.01% of portfolio
Latest Institutional Activity in CRVL
Top Purchases
Top Sells
About CRVL
CorVel Corporation provides workers' compensation, auto, liability, and health solutions for employers, third party administrators, insurance companies, and government agencies to assist them in managing the medical costs and monitoring the quality of care associated with healthcare claims. It applies technology, including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. The company offers network solutions services, including automated medical fee auditing, preferred provider management and reimbursement services, retrospective utilization review, facility claim review, professional review, pharmacy services, directed care services, Medicare solutions, clearinghouse services, independent medical examinations, and inpatient medical bill review. It also provides a range of patient management services, such as claims management, case management, 24/7 nurse triage, utilization management, vocational rehabilitation, and life care planning, as well as processing of claims for self-insured payors with respect to property and casualty insurance. The company was incorporated in 1987 and is headquartered in Fort Worth, Texas.
Insider Transactions at CRVL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 08
2025
|
Alan Hoops Director |
SELL
Payment of exercise price or tax liability
|
Direct |
996
-3.88%
|
$98,604
$99.83 P/Share
|
Jul 08
2025
|
Alan Hoops Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+25.95%
|
$99,000
$11.05 P/Share
|
Jun 09
2025
|
Brandon O'Brien Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,957
-25.11%
|
$427,356
$108.46 P/Share
|
Jun 09
2025
|
Maxim Shishin Chief Information Officer |
SELL
Open market or private sale
|
Direct |
2,400
-25.4%
|
$259,200
$108.09 P/Share
|
Jun 09
2025
|
Maxim Shishin Chief Information Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,400
+20.25%
|
$62,400
$26.5 P/Share
|
Jun 09
2025
|
Alan Hoops Director |
SELL
Open market or private sale
|
Indirect |
3,000
-2.54%
|
$324,000
$108.28 P/Share
|
Jun 05
2025
|
Brandon O'Brien Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,211
-12.3%
|
$243,210
$110.64 P/Share
|
Jun 05
2025
|
Brandon O'Brien Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,211
+10.95%
|
$86,229
$39.83 P/Share
|
Jun 05
2025
|
Brandon O'Brien Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
200
-1.25%
|
-
|
Jun 03
2025
|
Michael G Combs CEO & President |
SELL
Open market or private sale
|
Direct |
2,816
-5.98%
|
$315,392
$112.36 P/Share
|
Jun 02
2025
|
R Judd Jessup Director |
SELL
Open market or private sale
|
Direct |
6,351
-4.94%
|
$698,610
$110.41 P/Share
|
May 30
2025
|
R Judd Jessup Director |
SELL
Open market or private sale
|
Direct |
150
-0.12%
|
$16,650
$111.76 P/Share
|
May 29
2025
|
R Judd Jessup Director |
SELL
Open market or private sale
|
Direct |
687
-0.53%
|
$76,257
$111.25 P/Share
|
May 29
2025
|
Jennifer Yoss Vice President of Accounting |
SELL
Open market or private sale
|
Direct |
1,050
-33.46%
|
$116,550
$111.39 P/Share
|
May 29
2025
|
Jennifer Yoss Vice President of Accounting |
BUY
Exercise of conversion of derivative security
|
Direct |
1,050
+25.07%
|
$40,950
$39.83 P/Share
|
May 27
2025
|
R Judd Jessup Director |
SELL
Open market or private sale
|
Direct |
935
-0.72%
|
$105,655
$113.5 P/Share
|
May 27
2025
|
Alan Hoops Director |
SELL
Open market or private sale
|
Direct |
3,000
-15.24%
|
$339,000
$113.05 P/Share
|
May 27
2025
|
Mark E. Bertels EVP - Risk Management Services |
SELL
Open market or private sale
|
Direct |
900
-25.82%
|
$101,700
$113.34 P/Share
|
May 27
2025
|
Mark E. Bertels EVP - Risk Management Services |
BUY
Exercise of conversion of derivative security
|
Direct |
900
+20.52%
|
$23,400
$26.5 P/Share
|
May 22
2025
|
Brandon O'Brien Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
472
-1.45%
|
$53,808
$114.59 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 65.2K shares |
---|---|
Grant, award, or other acquisition | 142 shares |
Payment of exercise price or tax liability | 15.5K shares |
---|---|
Open market or private sale | 172K shares |
Bona fide gift | 66.5K shares |